Difference between revisions of "Idecabtagene vicleucel (Abecma)"

Revision as of 19:57, 2 April 2021

Anti-BCMA CAR T-cells.

3/26/2021: Approved for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

@@ Line 4: / Line 4: @@
 ==Diseases for which it is used==
 *[[Multiple myeloma]]
-# '''CRB-401:''' Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N, Kochenderfer JN. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019 May 2;380(18):1726-1737. [https://www.nejm.org/doi/full/10.1056/NEJMoa1817226 link to original article] [https://pubmed.ncbi.nlm.nih.gov/31042825 PubMed]
-# '''KarMMa:''' Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, Raje N, Lin Y, Siegel D, Oriol A, Moreau P, Yakoub-Agha I, Delforge M, Cavo M, Einsele H, Goldschmidt H, Weisel K, Rambaldi A, Reece D, Petrocca F, Massaro M, Connarn JN, Kaiser S, Patel P, Huang L, Campbell TB, Hege K, San-Miguel J. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021 Feb 25;384(8):705-716. [https://doi.org/10.1056/nejmoa2024850 link to original article] [https://pubmed.ncbi.nlm.nih.gov/33626253/ PubMed] NCT03361748
 ==History of changes in FDA indication==